Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

BACKGROUND: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience infiltrative cardiomyopathy and heart failure symptoms requiring costly hospitalizations. The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) demonstrated the efficacy of tafamidis on the frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Mark H., Tran, Diana, Bhambri, Rahul, Nativi-Nicolau, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270297/
https://www.ncbi.nlm.nih.gov/pubmed/35353352
http://dx.doi.org/10.1007/s40256-022-00526-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270297/
https://www.ncbi.nlm.nih.gov/pubmed/35353352
http://dx.doi.org/10.1007/s40256-022-00526-9

Ejemplares similares